Worth reading
57In focus
Scored from 5 of 6 sectionsDirection
Deterioration
Direction inferred from the company’s description.Scale
18
Year-on-year revenue growth (%)Wording
Conditional
How definitive the wording is.Results for this period
Interim period (second quarter)2022年7月1日〜2022年12月31日ConsolidatedJapanese GAAPNet Sales4,223,839thousand yenYear on year -18.0%
Operating profit344,523thousand yenYear on year -41.0%
Ordinary income345,351thousand yenYear on year -45.1%
Net income attributable to owners of the parent209,204thousand yenYear on year -49.6%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
Financial position at period-end
Total assets7,969,219thousand yen
of which net assets 6,929,881 thousand yen
The shaded area represents net assets as a proportion of total assets. It is calculated from the two amounts reported by the company.
Cash inflows and outflows
Operating-327,897
Investment-27,023
Financials-129,936
Net change-484,856
Stacked from zero: upward is an increase in cash, downward a decrease (in thousand yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period5,532,396 thousand yen
Segment revenueBiological Assessment Systems 258,436 thousand yen (YoY +11.8%), Healthcare Support 314,241 thousand yen (YoY -0.2%), Cosmetics 1,960,299 thousand yen (YoY -26.8%), Health Supplements 1,413,450 thousand yen (YoY -9.9%), Functional Materials Development 276,511 thousand yen (YoY -22.7%)
Segment profitBiological Assessment Systems 31,518 thousand yen, Healthcare Support 45,490 thousand yen (YoY -12.2%), Cosmetics 398,195 thousand yen (YoY -39.6%), Health Supplements -17,884 thousand yen, Functional Materials Development 42,700 thousand yen (YoY -32.4%)
Outlook and shareholder returns
Full-year earnings forecast
Net SalesNot disclosed
Operating profitNot disclosed
Ordinary incomeNot disclosed
Net incomeNot disclosed
Remarks2023年2月1日に修正した数値どおり予想
Factors Behind Changes in Business Performance
化粧品事業の中国市場向け商品の販売が現地国内メーカーの台頭による競争激化の影響等で減少。健康補助食品事業は広告料の高騰等で広告効率が悪化し、新規顧客の獲得数が前年同期を下回った。機能性素材開発事業はラクトフェリン原料の販売数量が伸び悩んだ。
Disclosure regarding the going concern assumption
Not applicable.
Change in accounting policy
基準改正に伴う変更 Yesそれ以外の変更 No見積りの変更 No修正再表示 No
Impairment loss当第2四半期連結累計期間は計上なし
Breakdown of extraordinary income (loss)Extraordinary income No recognition / Extraordinary loss Loss on Disposal of Fixed Assets 61 thousand yen
Depreciation and amortization9,213 thousand yen
Orders received and order backlog生体評価システム・評価試験 Orders received 127 million yen / Order backlog 150 million yen / 生体評価システム・医薬臨床研究支援 Orders received 72 million yen / Order backlog 158 million yen / Healthcare Support Orders received 314 million yen / Order backlog None
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2022年7月1日〜2022年12月31日 |
| Net Sales | 4,223,839 thousand yen (YoY -18.0%) |
| Operating profit | 344,523 thousand yen (YoY -41.0%) |
| Ordinary income | 345,351 thousand yen (YoY -45.1%) |
| Profit attributable to owners of the parent | 209,204 thousand yen (YoY -49.6%) |
| Total assets | 7,969,219 thousand yen |
| Net assets | 6,929,881 thousand yen |
| Cash flows from operating activities | -327,897 thousand yen |
| Cash flows from investing activities | -27,023 thousand yen |
| Cash flows from financing activities | -129,936 thousand yen |
| Cash and cash equivalents at end of period | 5,532,396 thousand yen |
| Full-year earnings forecast | Net Sales Not disclosed / Operating profit Not disclosed / Ordinary income Not disclosed / Net income Not disclosed / Remarks 2023年2月1日に修正した数値どおり予想 |
| Segment revenue | Biological Assessment Systems 258,436 thousand yen (YoY +11.8%), Healthcare Support 314,241 thousand yen (YoY -0.2%), Cosmetics 1,960,299 thousand yen (YoY -26.8%), Health Supplements 1,413,450 thousand yen (YoY -9.9%), Functional Materials Development 276,511 thousand yen (YoY -22.7%) |
| Segment profit | Biological Assessment Systems 31,518 thousand yen, Healthcare Support 45,490 thousand yen (YoY -12.2%), Cosmetics 398,195 thousand yen (YoY -39.6%), Health Supplements -17,884 thousand yen, Functional Materials Development 42,700 thousand yen (YoY -32.4%) |
| Orders received and order backlog | 生体評価システム・評価試験 Orders received 127 million yen / Order backlog 150 million yen / 生体評価システム・医薬臨床研究支援 Orders received 72 million yen / Order backlog 158 million yen / Healthcare Support Orders received 314 million yen / Order backlog None |
| Depreciation and amortization | 9,213 thousand yen |
| Impairment loss | 当第2四半期連結累計期間は計上なし |
| Breakdown of extraordinary income (loss) | Extraordinary income No recognition / Extraordinary loss Loss on Disposal of Fixed Assets 61 thousand yen |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards Yes / Other changes No / Change in accounting estimate No / Restatement No |
| Factors Behind Changes in Business Performance | 化粧品事業の中国市場向け商品の販売が現地国内メーカーの台頭による競争激化の影響等で減少。健康補助食品事業は広告料の高騰等で広告効率が悪化し、新規顧客の獲得数が前年同期を下回った。機能性素材開発事業はラクトフェリン原料の販売数量が伸び悩んだ。 |
Items this document does not state (14)
Net income per shareOperating MarginEquity ratioRevision to Earnings ForecastAnnual Dividend ForecastPayout ratioShareholder Return PolicyRegional salesChanges in the scope of consolidationMaterial subsequent eventsAvailability of Supplementary Financial Results MaterialsAvailability of Financial Results BriefingIssued Shares at Period-EndTreasury Shares at Period-End
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.化粧品事業では中国市場で現地国内メーカーの台頭により競争が激化し、健康補助食品事業では広告料の高騰などで広告効率が悪化した。機能性素材開発事業ではラクトフェリン原料の販売数量が伸び悩んだ。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.